GV-001 is a selective and orally active HDAC6 inhibitor with an IC 50 of 1.18 nM against HDAC6 . GV-001 selectively enhances α-tubulin acetylation, reduces sIL-6 and Collagen I levels, suppresses renal cyst growth, and upregulates PC1 expression. GV-001 can be used for the study of autosomal dominant polycystic kidney disease (ADPKD).
Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Renal Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Endocrinology | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Collagen | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Microtubule/Tubulin
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.